


ABOUT US
The Global CKD and Hypertension Pandemic affects 1.13 Billion people worldwide, inflicting death and suffering.
Global healthcare costs are estimated at over $500 Billion (1) a year.
Hypertension is one of the main causes of CKD - costing Medicare, in the USA alone,
over $84 billion (2,3) a year.
The only current solution, Dialysis, dramatically reduces patients' quality-of-life
– 5-year patient survival probability for all renal replacement therapy - 50.8% (4).
CureSpec was Founded in 2020.
Our first market-ready product, Nephrospec™ is intended for the interrelated treatment of:
- CKD (Chronic Kidney Disease)
- Hypertension (High Blood Pressure)
NephroSpec - Saving lives & costs
NephroSpec promotes new blood vessel formation and restores damaged tissue
function by means of its patented ShockWave technology.
We hold an Established, market-ready product, with a strong IP portfolio, which includes a granted U.S. patent,
a fully developed CE-Marked device & Promising preliminary clinical results.
CureSpec has an established Production facility, a Global distribution chain and an experienced management team.
-
https://www.cdc.gov/chronicdisease/programs-impact/pop/high-blood-pressure.htm
-
Gaziano TA, Asaf B, S Anand, et.al. The global cost of non-optimal blood pressure. J Hypertens. 2009
-
Kramer A, Boenink R, Noordzij M, et al. The ERA-EDTA Registry Annual Report 2017 : a summary. 2020
Nephrospec - a medical device manufactured by Curespec.
Nephrospec - a safe, non-invasive shockwave device intended for the treatment of CKD and Hypertension
Nephrospec - promotes new blood vessel formation and restores damaged tissue function through its patented technology
Nephrospec - saves up to 80% of costs while easing suffering and needless loss of lives
Benefits include:
-
Complementary solution to optimal medical care for CKD and hypertension
-
Kidney function improvement in weeks
-
Outpatient treatment delays onset of dialysis
TM
TM
TM
TM

OUR PRODUCT

Pre treatment
ARAS Kidney

Post Shockwave treatment
Curespec uses shockwave technology to produce a neovascularization affect on the kidneys.
CLINICAL
Our Team

Avner Spector
Founder, Active Chairman
Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies in Israel and the US. He holds a B.Sc. Degree in Mechanical Engineering from Ben-Gurion-University of the Negev, Israel.

Ophir Brandt
CFO
Mr. Brandt is a Certified Public Accountant (CPA) from the Bar-Ilan University, and holds an MBA degree from the Hebrew University. Mr. Brandt has over 10 years of experience in financial management, including as a CFO in the private sector and as a Senior Auditor at Ernst & Young (EY).